Table 2.
Univariate and multivariate associations with IPSS sum increase ≥5
| Variables | Associated level | IPSS sum increase ≥5 | |
|---|---|---|---|
| Hazard ratio (95% CI) | p-value | ||
| Univariate analysis | |||
| Race | African American | 1.276 (0.662–2.460) | 0.467 |
| Diabetes | Yes | 0.917 (0.535–1.570) | 0.752 |
| Smoking | Yes | 1.105 (0.894–1.366) | 0.357 |
| Risk group* | High | 1.064 (0.788–1.438) | 0.684 |
| ADT | Yes | 1.210 (0.806–1.816) | 0.358 |
| IGRT | Yes | 1.194 (0.718–1.984) | 0.494 |
| Positioning | Prone | 1.200 (0.723–1.993) | 0.481 |
| Cone down | Yes | 0.853 (0.510–1.427) | 0.544 |
| Age (years) | Continuous | 1.010 (0.982–1.039) | 0.495 |
| Prostate volume (cm3)# | Continuous | 1.003 (0.994–1.012) | 0.520 |
| Bladder volume (cm3) | Continuous | 1.000 (0.999–1.001) | 0.974 |
| Cross-sectional rectal area (cm2) | Continuous | 0.947 (0.871–1.029) | 0.199 |
| Craniocaudal extent of SV (cm) | Continuous | 1.142 (0.828–1.573) | 0.419 |
| Baseline IPSS sum | Continuous | 0.926 (0.891–0.963) | <0.0001 |
| Mean BW dose (Gy) | Continuous | 0.999 (0.981–1.017) | 0.914 |
| Maximal BW dose (Gy) | Continuous | 1.250 (1.018–1.534) | 0.033 |
| Multivariate analysis | |||
| Baseline IPSS sum | Continuous | 0.929 (0.894–0.966) | <0.0001 |
| Maximal BW dose (Gy) | Continuous | - | - |
Abbreviations:
*
according to the National Comprehensive Cancer Network (NCCN);
#
information lacking for 11 patients;
ADT=androgen deprivation therapy; IGRT=image guided radiation therapy; SV=seminal vesicles; BW=bladder wall; IPSS= International Prostate Symptom Score.